25
Feb

Eli Lilly says its closely-watched GLP-1 diabetes drug dulaglutide works as well as the market leading therapy Victoza, but isn’t superior to the rival drug. That’s going to be good enough for Lilly to claim a big win, though, as analysts were ready to hand it a victory on non-inferiority for a drug now in the hands of regulators.

…read more

Source: Lilly’s dulaglutide hits the mark for comparability to Victoza in a blockbuster showdown

    

0 No comments